Media Coverage

Aratana set to launch Entyce in US after delays


Oct 16, 2017 - Animal Pharm
By Sian Lazell
Animal Pharm
October 16, 2017


Pet health specialist Aratana Therapeutics is making its Entyce appetite stimulant for dogs available to US veterinarians.

Entyce (capromorelin oral solution) is a ghrelin receptor agonist and the only canine appetite stimulant approved by the US FDA. The product was Aratana's second FDA approval, licensed in May 2016.

In February, Leawood, Kansas-based Aratana revealed it was working to transfer the manufacturing of Entyce to a new vendor. As part of the process, the FDA requested additional information "regarding the proposed transfer in order to complete the supplemental application", leading to a delayed commercial launch of the product. The firm subsequently set a new launch date for fall 2017.

Despite the delay, global investment banking and wealth management firm William Blair said it remained confident in Aratana, commenting that the decline in the firm's share price at the time could make an "attractive entry point" for smaller capitalization investors.

Following recent approval from the FDA's Center for Veterinary Medicine for the transfer and scale-up of manufacturing, US veterinarians can now order Entyce through an Aratana specialist or a preferred distributor partner. Shipments are expected to begin by the end of October. Entyce is administered once-daily and is available as a flavored oral solution in 10ml, 15ml and 30ml bottles.

Ernst Heinen, chief development officer at Aratana, said: "We know improper food intake inhibits the overall health of the dog and has a negative impact on a dog's quality of life. Nutrition is so imperative – veterinarians and pet owners often use appetite as a fifth vital sign and go to great lengths to address inappetence. Entyce was developed specifically to stimulate appetite and provides the first therapeutic based on the natural physiology of appetite."

Aratana said veterinarians see over 10 million dogs in the US each year affected by inappetence. The problem can be caused by a range of both chronic diseases or acute conditions.

In an updated outlook on the product ahead of its imminent commercial launch, William Blair commented: "We believe that this is a significant and positive milestone for Aratana, although it is also in line with recent management communications regarding launch timing.

"Entyce is the only therapeutic approved by the FDA to stimulate appetite in dogs and Aratana retains all rights to the product. Management has noted that inappetence affects 10 million dogs annually and the product has reportedly attracted significant interest among vets since approval."

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum